McKesson (MCK) Stock Forecast & Price Target

Q: What analysts cover McKesson?

McKesson has been rated by research analysts at Barclays , Citigroup , Evercore , Leerink Partners , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , TD Cowen , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$930.64 +20.32 (+2.23%)

Closing price 10/8/2026 03:59 PM Eastern

Extended Trading

$929.10 -1.55 (-0.17%)

As of 09:07 AM Eastern

Compare

McKesson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for MCK.

Consensus Price Target

$973.19
4.57% Upside

According to the 18 analysts' twelve-month price targets for McKesson, the average price target is $973.19. The highest price target for MCK is $1,080.00, while the lowest price target for MCK is $845.00. The average price target represents a forecasted upside of 4.57% from the current price of $930.65.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCK Analyst Ratings Over Time

Type	Current Forecast 10/9/25 to 10/9/26	1 Month Ago 9/9/25 to 9/9/26	3 Months Ago 7/11/25 to 7/11/26	1 Year Ago 10/9/24 to 10/9/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	11 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$973.19	$973.44	$960.53	$829.08
Forecasted Upside	4.57% Upside	8.84% Upside	19.28% Upside	9.37% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

McKesson Stock vs. The Competition

Type	McKesson	Healthcare Companies	Broader Market
Consensus Rating Score	2.78	2.32	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	4.57% Upside	903.14% Upside	19.64% Upside
News Sentiment Rating	Positive News See Recent MCK News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/7/2026	Leerink Partners 2 of 5 stars	Michael Cherny 4 of 5 stars	Boost Target	Outperform	$1,030.00 ➝ $1,070.00	+16.99%
10/6/2026	Morgan Stanley 3 of 5 stars	Erin Wright 4 of 5 stars	Set Target		$977.00	+5.76%
9/14/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Reiterated Rating	Sector Perform	$845.00	-5.64%
9/4/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy (B-) ➝ Buy (B)
8/19/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$925.00 ➝ $1,000.00	+14.98%
8/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$812.00 ➝ $933.00	+6.26%
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$1,015.00	+20.43%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
8/6/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$989.00 ➝ $1,006.00	+15.47%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,050.00 ➝ $1,080.00	+23.97%
Get the Latest News and Ratings for MCK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.
7/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$945.00 ➝ $1,000.00	+21.26%
5/8/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$875.00	+15.73%
5/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,107.00 ➝ $1,015.00	+37.07%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
4/6/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,040.00 ➝ $1,000.00	+16.29%
3/5/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$970.00	+4.12%
2/5/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$880.00 ➝ $885.00	+7.98%
11/25/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/13/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$820.00 ➝ $900.00	+17.07%
4/4/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Sundaram Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:14 AM ET.

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 5, 2026. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

Here are some ways that investors could benefit from investing in McKesson Co.:

McKesson Co. recently reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, a move that provided immediate revenue visibility and contributed to the stock trading at $915.98 as of October 5, 2026.
The company demonstrated strong financial performance in its most recent quarter, reporting revenue of $105.38 billion and adjusted earnings per share of $9.93, which beat analyst consensus estimates of $9.56 and signaled durable operating momentum.
Management has expressed confidence in future growth by raising its fiscal 2027 adjusted earnings per share guidance to a range of $44.20 to $45.00, indicating an expectation of continued profitability and operational efficiency.
McKesson Co. is expanding its strategic footprint by finalizing a deal with CD&R to acquire Option Care Health for over $5 billion, which will enhance its capabilities in infusion services and healthcare delivery.
The stock exhibits low volatility with a beta of 0.30, suggesting it may offer a defensive profile for investors seeking stability, while also providing a dividend yield of 0.42% with a recent increase in the quarterly payout to $0.94 per share.

McKesson
Bear Case

Investors should be bearish about investing in McKesson Co. for these reasons:

Corporate insiders have shown a consistent pattern of selling, with 11 sales recorded in the past six months and zero purchases, including significant reductions in holdings by CEO Brian Tyler and other executives.
Short interest in the stock has increased recently, rising to 2,903,573 shares as of the September 15, 2026 record date, which represents a 2.42% month-over-month increase and suggests some market participants are betting against the stock.
The company's valuation is relatively high with a price-to-earnings ratio of 24.51, which may limit upside potential if earnings growth does not continue to outpace the current stock price of $915.98.
Several institutional investors, including Park National Corp OH and CX Institutional, have reduced their positions in the third quarter, with CX Institutional cutting its stake by 50.5%, indicating a potential shift in institutional sentiment.
McKesson Co. reported a negative return on equity of 253.21% in its latest quarterly results, a metric that reflects the company's capital structure and leverage, which may concern investors focused on traditional profitability ratios.

MCK Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $973.19, with a high forecast of $1,080.00 and a low forecast of $845.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 4.57% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 1 upgrade by analysts.

McKesson has been rated by research analysts at Barclays, Citigroup, Evercore, Leerink Partners, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "healthcare" companies. The consensus rating for McKesson is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MCK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With McKesson Recommendations

MarketBeat monitors more than a dozen sources for McKesson analyst ratings, with the most recent rating issued on 10/7/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

McKesson (MCK) Stock Forecast & Price Target